In this year’s conference on Wednesday, June 21 (agenda below), we address the question of how to implement and disseminate these business models head on. Fortunately there are already several enterprises, some of them led by patients themselves, which provide us early answers to these questions. These are featured in our first panel entitled Early Disruptors in Precision Medicine.
Read Full Release
BOSTON and NEW YORK, June 20, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Pamplona Capital Management, LLP (Pamplona) today announced that they have entered into a definitive agreement under which Pamplona will acquire all of the outstanding shares of PAREXEL for $88.10 per share in cash in a transaction valued at approximately $5.0 billion, including PAREXEL’s net debt.
Read Full Release
IBM Watson Health, Cota Healthcare and Hackensack Meridian Health are partnering to test clinical decision support in cancer treatment, a pilot that will draw on Cota's precision-medicine database and Watson Health's artificial intelligence-enabled evidence-based recommendations.
Read Full Release
Danbury, Conn. (May 18, 2017) — Odyssey Logistics & Technology Corp. (Odyssey), a global leading logistics provider, today announced that it has been positioned by Gartner, Inc. on the “Magic Quadrant for Third Party Logistics Providers, North America” for 2017. This marks the first time Odyssey has been placed on the Gartner Magic Quadrant.
Read Full Release
MassBio Lunch and Learn: Navigating Accelerated Approvals in Today’s Oncology Drug Development Landscape: Ensuring a Properly Tailored Approached Based on FDA Expectations and Current Trends in Drug Development
Read Full Release
Imagine waiting for your diagnosis. The doctor walks in and says, “Well, I just consulted with everyone on the planet Earth over the last 30 years to see how they took care of people like you, and then I looked at a database that precisely looked at people who have exactly what you have, and are exactly like you, and this is what I have learned in the past five minutes, and this is why I am going to recommend this treatment.”
Read Full Release
BC Platforms, a world leader in genomic data management solutions, today announces that it has closed a $USD 10 million financing round. The round was led by Debiopharm Innovation Fund in conjunction with Tesi, a Finnish venture capital and private equity company, and was supported by BC Platforms’ existing investors. BC Platforms will use the funds to launch new technologies in 2017 integrating complex clinical and genomic data in order to deliver precision medicine and clinical patient benefits, as well as to grow its existing genomic data management software business worldwide.
Read Full Release
Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients.
As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will leverage Cota's research-grade, real-world evidence, web-based analysis and visualization tools, and be supported by Cota's medical, data science, and technology experts. Utilizing the real-world evidence and technology platform supplied by Cota is expected to enable Novartis Pharmaceuticals Corporation to accelerate clinical development of new therapies for breast cancer and identify which patients will benefit most.
Read Full Release
Bivarus, a patient-centered analytics company working with healthcare organizations to measure and analyze the patient experience and employee engagement, announced today it raised $4 million in a Series B from existing investors. Hatteras Venture Partnersled this latest financing round. Other participants in the round include Excelerate Health Ventures, Nashville-based NueCura Partners and Boston Millennia Partners.
Read Full Release
